Adma Biologics, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.admabiologics.com

Moat Score

Market Cap $4.43B
PE 65
Debt $NaN
Cash $86.71M
EV $NaN
FCF $79.39M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$68.13M
EBIT	$114.89M
ROE	29%
ROA	29%
FCF	$79.39M
Equity	$231.89M
Growth Stability	1
PE	64.98
PB	19.09
P/FCF	55.77
P/S	11.56
Price/Cash	0.02
Net Margins	28%
Gross Margins	49%
Op. Margins	30%
Sales Growth YoY	78%
Sales Growth QoQ	12%
Sales CAGR	56%
FCF CAGR	0%
Equity CAGR	49%
Earnings Growth YoY	1K%

Earnings Growth QoQ	12%
Sales CAGR 5Y	75%
FCF CAGR 5Y	2%
Equity CAGR 5Y	28%
Earnings CAGR 3Y	75%
Sales CAGR 3Y	75%
FCF CAGR 3Y	24%
Equity CAGR 3Y	19%
Market Cap	$4.43B
Revenue	$382.81M
Assets	$390.62M
Cash	$86.71M
Shares Outstanding	231.96M
Moat Score	97%
Working Capital	273.3M
Current Ratio	7.09
Gross Profit	$187.31M
Shares Growth 3y	14%
Equity Growth QoQ	23%
Equity Growth YoY	53%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

SEC Filings

Direct access to Adma Biologics, Inc. (ADMA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Adma Biologics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Adma Biologics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Adma Biologics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Adma Biologics, Inc..

Years

Calculation mode

= $802M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$79M	$80M	$80M	$80M	$80M	$80M	$80M	$80M	$80M	$80M	$81M	$806M
DCF		$72M	$66M	$60M	$55M	$50M	$45M	$41M	$37M	$34M	$31M	$311M
Value	$802M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-284%	-250%	-183%	-192%	-387%	-165%	-179%	-89%	-43%	-11%	28%
ROA	-	-65%	-73%	-36%	-68%	-33%	-31%	-21%	-11%	7%	29%
ROE	-	-2K%	438%	-108%	-333%	-184%	-86%	-51%	-43%	-21%	29%

Good Net Margins (27.77%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0	-0.43	-0.07	-0.46	-0.91	-	-	-	-	-
Debt over Equity	-	0	-1.77	0.07	1.52	2.77	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	21%	49%	113%	-25%	73%	44%	92%	90%	68%	75%
Earnings YoY growth	-	7%	9%	124%	50%	-27%	57%	-5%	-8%	-57%	-
Equity YoY growth	-	-86%	-643%	-1K%	-51%	32%	237%	60%	8%	-11%	28%
FCF YoY growth	-	-9%	19%	118%	62%	24%	43%	10%	-42%	-105%	2%